Unicycive Therapeutics, Inc.
No enriched coverage for $UNCY in the last 7 days.
No SEC Form 4 filings for $UNCY in the last 30 days.
Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
Kirby McInerney LLP said it is investigating potential federal securities-law claims against Unicycive Therapeutics (NASDAQ:UNCY). The firm cites Unicycive’s June 30, 2026 FDA second Complete Response Letter for oxylanthanum carbonate, tied to prior manufacturing deficiencies. Unicycive shares fell about 39% from $7.70 to $4.69 that day; no lawsuit has been filed.
Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001766140 0001766140 2026-06-19 2026-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
Recent UNCY coverage spans financial news, corporate actions and regulation.
The CRL introduces a regulatory/manufacturing overhang that can delay approval timing despite no safety/efficacy concerns.
A second CRL for oxylanthanum carbonate renews regulatory uncertainty and highlights unresolved third-party manufacturing issues.
Routine shareholder-meeting outcomes; no new operating, financial, or regulatory catalyst disclosed beyond governance votes.
The company expands its at-the-market (ATM) equity issuance capacity and files an updated shelf registration, increasing potential dilution over time.
The investigation into Unicycive Therapeutics, Inc. (UNCY) suggests potential corporate misconduct, which may negatively impact the company's stock performance. The bearish sentiment indicates increased risk for investors.
alphai scores every news story that mentions UNCY with an AI model for sentiment and relevance, and aggregates insider trades from Unicycive Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
7 min readKirby McInerney LLP said it is investigating potential federal securities-law claims against Unicycive Therapeutics (NASDAQ:UNCY). The firm cites Unicycive’s June 30, 2026 FDA second Complete Response Letter for oxylanthanum carbonate, tied to prior manufacturing deficiencies. Unicycive shares fell about 39% from $7.70 to $4.69 that day; no lawsuit has been filed.
3 min readUnicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001766140 0001766140 2026-06-19 2026-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
3 min readUnicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001766140 0001766140 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readBronstein, Gewirtz & Grossman, LLC is investigating potential claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased securities before March 29, 2024. The investigation seeks to determine if Unicycive and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist with the investigation.
3 min readGrabar Law Office is investigating potential breaches of fiduciary duties by officers and directors of Integer Holdings Corp. (NYSE: ITGR), Molina Healthcare, Inc. (NYSE: MOH), Unicycive Therapeutics, Inc. (NASDAQ: UNCY), and WEBTOON Entertainment Inc. (NASDAQ: WBTN). Shareholders who held shares of these companies before specific dates are encouraged to contact the law office to explore options for corporate reforms and the return of funds. The investigations cite alleged misleading statements and failures to disclose material adverse facts to investors.
2 min readGrabar Law Office is investigating claims on behalf of long-term shareholders of Boston Scientific, Corcept Therapeutics, Nektar Therapeutics, and Unicycive Therapeutics regarding alleged breaches of fiduciary duty by officers and directors. The investigations stem from recent federal securities fraud class action lawsuits or emerging disclosures about company performance and regulatory issues. Shareholders who purchased shares before specific dates are encouraged to contact the law office to potentially seek corporate reforms and other remedies at no cost.
3 min readBronstein, Gewirtz & Grossman, LLC has launched an investigation into Unicycive Therapeutics, Inc. (UNCY) based on potential corporate wrongdoing. The firm is encouraging shareholders who purchased Unicycive securities before March 29, 2024, and continue to hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis for class actions, only seeking reimbursement if successful in recovering investor capital.
3 min readBronstein, Gewirtz & Grossman, LLC has launched an investigation into Unicycive Therapeutics, Inc. (NASDAQ: UNCY) concerning potential corporate wrongdoing. The firm encourages shareholders who purchased Unicycive securities before March 29, 2024, and still hold them, to contact them for more information and to assist in the investigation. The investigation focuses on whether Unicycive and its officers engaged in misconduct.
2 min readLOS ALTOS, Calif., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Unicycive Therapeutics, Inc. ( Nasdaq: UNCY ) , a clinical-stage biotechnology company developing therapies for patients with kidney disease ( the "Company" or "Unicycive" ) , today announced that Shalabh Gupta, M.D., Chief Executive ...
3 min read
